Richard A. Miller MD - 13 Dec 2022 Form 4 Insider Report for Corvus Pharmaceuticals, Inc. (CRVS)

Role
President and CEO, Director
Signature
/s/ Leiv Lea, as Attorney-in-Fact for Richard A. Miller
Issuer symbol
CRVS
Transactions as of
13 Dec 2022
Net transactions value
+$44,827
Form type
4
Filing time
15 Dec 2022, 15:32:20 UTC
Previous filing
28 Sep 2022
Next filing
16 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRVS Common Stock Purchase $37,015 +50,000 +3.5% $0.7403 1,480,119 13 Dec 2022 By Trust F1, F2, F3
transaction CRVS Common Stock Purchase $7,812 +10,000 +0.68% $0.7812 1,490,119 14 Dec 2022 By Trust F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.73 to $0.7580, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2 Includes 35,714 shares previously held directly.
F3 These shares are held by Richard A. Miller and Sandra J. Horning, Trustees of the Miller-Horning Family Trust u/a/d January 25, 1985 (the "Miller-Horning Trust"). Dr. Miller has shared voting, investment and dispositive power over the shares held by the Miller Horning Trust.
F4 The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.7798 to $0.7899, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.